



Oliphant, R., Horgan, P. G., Morrison, D. S., and McMillan, D. 
C. (2014) Validation of a modified clinical risk score to predict cancer-
specific survival for stage II colon cancer. Cancer Medicine. ISSN 2045-
7634 
 
































Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
ORIGINAL RESEARCH
Validation of a modified clinical risk score to predict
cancer-specific survival for stage II colon cancer
Raymond Oliphant1,2, Paul G. Horgan1,3, David S. Morrison2 & Donald C. McMillan1 In collaboration
with the West of Scotland Colorectal Cancer Managed Clinical Network
1University Department of Surgery, Faculty of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G4 0SF, U.K.
2West of Scotland Cancer Surveillance Unit, Institute of Health and Wellbeing, University of Glasgow, Glasgow, G12 8RZ, U.K.
3West of Scotland Colorectal Cancer Managed Clinical Network, Glasgow Royal Infirmary, Glasgow, G4 0SF, U.K.
Keywords
Clinical risk score, colon cancer, Stage II,
survival
Correspondence
Raymond Oliphant, West of Scotland Cancer
Surveillance Unit, Institute of Health and
Wellbeing, 1 Lilybank Gardens, University of
Glasgow, Glasgow, G12 8RZ, U.K.
Tel: 0141 330 3281; Fax: 0141 330 5018;
E-mail: raymondoliphant@nhs.net
Funding Information
No funding information provided.
Received: 2 July 2014; Revised: 12 August
2014; Accepted: 20 August 2014
doi: 10.1002/cam4.352
Abstract
Many patients with stage II colon cancer will die of their disease despite cura-
tive surgery. Therefore, identification of patients at high risk of poor outcome
after surgery for stage II colon cancer is desirable. This study aims to validate a
clinical risk score to predict cancer-specific survival in patients undergoing sur-
gery for stage II colon cancer. Patients undergoing surgery for stage II colon
cancer in 16 hospitals in the West of Scotland between 2001 and 2004 were
identified from a prospectively maintained regional clinical audit database.
Overall and cancer-specific survival rates up to 5 years were calculated. A total
of 871 patients were included. At 5 years, cancer-specific survival was 81.9%
and overall survival was 65.6%. On multivariate analysis, age ≥75 years (hazard
ratio (HR) 2.11, 95% confidence intervals (CI) 1.57–2.85; P<0.001) and emer-
gency presentation (HR 1.97, 95% CI 1.43–2.70; P<0.001) were independently
associated with cancer-specific survival. Age and mode of presentation HRs
were added to form a clinical risk score of 0–2. The cancer-specific survival at
5 years for patients with a cumulative score 0 was 88.7%, 1 was 78.2% and 2
was 65.9%. These results validate a modified simple clinical risk score for
patients undergoing surgery for stage II colon cancer. The combination of these
two universally documented clinical factors provides a solid foundation for the
examination of the impact of additional clinicopathological and treatment fac-
tors on overall and cancer-specific survival.
Introduction
Colon cancer is one of the commonest causes of cancer
death in Western Europe and North America.1 Despite
overall improvements in relative survival over recent
decades, many patients still present with locally
advanced or metastatic disease.2 Even in those undergo-
ing surgical resection with curative intent for stage II
colon cancer, between 20 and 30% will die of their dis-
ease within 5 years.2–4 As a result of these poor out-
comes there is increasing interest in the use of
adjuvant chemotherapeutic regimens in patients with
stage II colon cancer who are at high risk of dying
from their disease.5 With the introduction of nationally
coordinated bowel screening programs and the pro-
jected rise in the proportion of early stage disease,6,7
the need to identify those at high risk has become
increasingly important.
A previously published clinical risk score8 was devised
as a starting point for the identification of high-risk stage
II colon cancer patients using routinely collected clinical
information. The score uses age (<75 or ≥75 years), mode
of presentation (elective or emergency), and occurrence
of anastomotic leak (yes or no) to simply and reliably aid
identification of patients at risk of poorer longer term
cancer-specific survival. However, this score used data
from an era (1991–1994) prior to the emergence of surgi-
cal specialization, advances in preoperative imaging (e.g.,
routine CT scanning) and in peri- and postoperative
patient care.9 Validation of this clinical risk score in a
newer cohort of patients undergoing surgery for colon
cancer is therefore required.
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Therefore, the aim of this study was to evaluate and
externally validate a clinical risk score to predict 1-, 3-,
and 5-year cancer-specific survival in patients undergoing
surgery for stage II colon cancer.
Methods
Clinical audit data of patients undergoing surgery for
AJCC stage II (TMN pT3-4 pN0 pM0) colon cancer in 16
hospital sites from 1 January 2001 to 31 December 2004
were extracted from the prospectively maintained data-
base of the West of Scotland Colorectal Cancer Managed
Clinical Network. Individual patient records were then
linked to the Scottish Cancer Registry (SMR06). Details
included age, gender, deprivation (DEPCAT), site of
tumor, mode of presentation, speciality of surgeon, anas-
tomotic leak, and adjuvant therapy.
Colon cancers (C18) were classified according to their
anatomical site as per the International Classification of
Disease version 10 (ICD-10). Tumors of the rectosigmoid
(C19), rectum (C20), anus and anal canal (C21), and
appendix (C18.1) were excluded. Mode of presentation
was defined as emergency if presentation was with signifi-
cant rectal bleeding, intestinal obstruction, perforation, or
other presentations resulting in an unplanned emergency
hospital admission. All other routes of presentation were
considered elective. The extent of spread was assessed by
conventional AJCC staging classification based on histo-
logic examination of the resected specimen. Individual
surgeons were identified as colorectal specialists or non-
specialists by panel members of the corresponding local
multidisciplinary team (MDT) of the surgical units under
study using a similar method as previously described.10
These assessments were made without prior knowledge of
the outcome and before any analyses were performed.
Anastomotic leak was defined as a composite of both
radiological and clinical leaks diagnosed <30-days of sur-
gery. Patients’ socioeconomic circumstances were inferred
using the 2001 DEPCAT, a validated categorical score that
ranks residential postcodes from 1 (most affluent) to 7
(most deprived) using four Census variables that were
found to best predict health outcomes—car ownership,
unemployment, overcrowding, and lower occupational
social class (IV and V).11 They were further grouped into
three conventional categories: 1 and 2 (affluent); 3–5
(intermediate); and 6 and 7 (deprived).
Patient records were linked to the General Registry
Office for Scotland (GROS) death records. Survival time
was calculated from date of surgery to date of death or
censor with a minimum of 5-year follow up (date of cen-
sor 31 December 2010). Postoperative mortality was
defined as any death occurring within 30 days of initial
surgery. Those dying within this period were excluded
from further analyses. Cancer-specific deaths were deter-
mined as a first, or principal underlying cause of death
with International Classification of Disease (ICD) 10
codes for colorectal cancer, C18 to C20, as well as C26
and C80. Overall survival was determined as death from
any cause.
Grouping of the variables was carried out using con-
ventional categories. Univariate and multivariate survival
analysis and calculation of hazard ratios (HRs) were
carried out using Cox’s proportional hazards model.
The method used to calculate the original score has
been published previously 8 and was used to validate
the score in the present cohort. Cumulative survival
following surgery was estimated using the Kaplan–Meier
method and the log-rank used to test for independence
between variables. Predictive model analysis using recei-
ver operating characteristic analysis was carried out. C-
statistics were calculated with the null hypothesis that
the true area under the curve was 0.5, and asymptotic
95% confidence intervals (95% CIs) calculated around
the best estimate. P < 0.050 was considered statistically
significant throughout. Analysis was performed using
the Stata software package version 11 IC (Statacorp,
College Station, TX).
The West of Scotland Cancer Surveillance Unit
obtained permission to obtain cancer registry data both
from Caldicott Guardians of all health boards in the West
of Scotland and from the Information Services Division
of the NHS in Scotland privacy advisory committee. Per-
mission to obtain clinical audit data was granted by the
West of Scotland Colorectal Cancer Managed Clinical
Network advisory board.
Results
Of the 937 patients who underwent a resection for stage
II colon cancer, there were 66 (7.0%) postoperative
deaths and 871 patients were included in the analysis.
The majority were aged <75 years (61.4%), were not
socioeconomically deprived (72.7%), presented electively
(76.0%) and were treated by a specialist colorectal sur-
geon (66.6%). A total of 16 (1.8%) patients developed an
anastomotic leak and 111 (12.7%) received adjuvant che-
motherapy. At 5 years, cancer-specific survival was 81.9%
and overall survival was 65.6%.
The relationship between clinicopathological character-
istics and cancer-specific survival is shown in Table 1. On
univariate analysis, age (P < 0.001), specialty of surgeon
(P = 0.038) and mode of presentation (P < 0.001) were
significantly associated with cancer-specific survival. On
multivariate analysis of these factors, age ≥75 years (HR
2.11, 95% CI = 1.57–2.85, P < 0.001) and emergency pre-
sentation (HR 1.97, 95% CI = 1.43–2.70, P < 0.001) were
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independently associated with cancer-specific survival
(Table 1).
The relationship between clinicopathological character-
istics and overall survival is shown in Table 2. On univar-
iate analysis, age (P < 0.001), mode of presentation
(P < 0.001), and adjuvant chemotherapy (P = 0.003) were
significantly associated with overall survival. On multivar-
iate analysis of these significant factors, age ≥75 years
(HR 2.64, 95% CI = 2.64–3.3, P < 0.001) and emergency
presentation (HR 1.70, 95% CI = 1.36–2.14, P < 0.001)
were independently associated with overall survival
(Table 2).
With reference to cancer-specific survival in colon can-
cer, as the magnitude of the covariates (HRs) of age
≥75 years (2.11) and emergency presentation (1.97) were
similar, they could be allocated a score of 1 if they
occurred and 0 if absent. Together these factors could be
simply added to form a modified clinical risk score
(excluding anastomotic leak) from 0 to 2. The relation-
ship between such a cumulative prognostic score and
1-, 3-, and 5-year cancer-specific survival is shown in
Figure 1.
In patients with stage II colon cancer, the cancer-spe-
cific survival rates at 3 years for patients with a
cumulative score 0 was 91.9%, 1 was 82.7%, and 2 was
74.4% (Table 3). The cancer-specific survival rates at
5 years for patients with a cumulative score 0 was 88.7%,
1 was 78.2%, and 2 was 65.9%. The area under the curve
for the clinical risk score with cancer-specific mortality as
an end point at 1, 3, and 5 years was (0.658, 95%
CI = 0.582–0.733, P < 0.001), (0.629, 95% CI = 0.581–
0.678, P < 0.001), and (0.626, 95% CI = 0.582–0.670,
P < 0.001), respectively.
Discussion
This study shows that in a large cohort of patients
undergoing surgical resection for stage II colon cancer,
a simple clinical risk score using age and mode of
presentation clearly identifies differences in 1-, 3-, and
5-year cancer-specific survival. Unlike the previously
published version of this score,8 anastomotic leak was
not associated with cancer survival in this series and
was therefore not used a covariable in the modified
score construct. Despite this modification, this simple
clinical risk score identified variations in 5-year cancer-
specific survival of between 88.7% and 65.9% in those
with stage II colon cancer.
Table 1. Relationship between clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for stage II colon can-
cer: univariate and multivariate analysis.
Risk factor Patients (n = 871) Univariate HR (95% CI) P-value Multivariate HR (95% CI) P-value
Age in years (<75/≥75) 535/336 2.08 (1.55, 2.81) <0.001 2.11 (1.57, 2.85) <0.001
Gender (Male/Female) 426/445 0.81 (0.60, 1.09) 0.159




Mode of presentation (elective/emergency) 662/209 2.01 (1.48, 2.74) <0.001 1.97 (1.43, 2.70) <0.001
Specialization (yes/no) 580/291 1.38 (1.02, 1.87) 0.038 1.17 (0.85, 1.60) 0.333
Leak (no/yes) 855/16 1.01 (0.32, 3.16) 0.987
Chemo (no/yes) 760/111 1.06 (0.70, 1.60) 0.794
1Baseline—affluent.
Table 2. Relationship between clinicopathological characteristics and overall survival in patients undergoing surgery for stage II colon cancer: uni-
variate and multivariate analysis.
Risk factor Patients (n = 871) Univariate HR (95% CI) P-value Multivariate HR (95% CI) P-value
Age in years (<75/≥75) 535/336 2.69 (2.18, 3.33) <0.001 2.64 (2.1, 3.3) <0.001
Gender (Male/Female) 426/445 0.86 (0.69, 1.06) 0.146




Mode of presentation (elective/emergency) 662/209 1.63 (1.30, 2.05) <0.001 1.70 (1.36, 2.14) <0.001
Specialization (yes/no) 580/291 1.21 (0.98, 1.51) 0.081
Leak (no/yes) 855/16 1.00 (0.44, 2.24) 0.994
Chemo (no/yes) 760/111 0.56 (0.39, 0.82) 0.003 0.83 (0.56, 1.23) 0.352
1Baseline—affluent.
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Contrary to our findings, a number of large cohort
studies indicate that postoperative anastomotic leakage is
associated with poor long-term survival in colorectal and
gastric cancer.12–14 The apparent lack of association in
our study may be partially explained by the relatively low
anastomotic leak rate (1.8%) and the total number of
patients included was not large enough to detect a signifi-
cant survival disadvantage. In addition, those experiencing
a leak are more likely to have died within 30-days of sur-
gery and as such excluded from this analysis. The diagno-
sis of anastomotic leakage may also have changed since
the time period from which the original clinical risk score
was described (1991–1994) due to the increased use
cross-sectional imaging (e.g., CT scanning). Previously,
anastomotic leakage would have been diagnosed during
an unplanned return to theater in the immediate postop-
erative period or by using less sensitive contrast radiology
techniques. Thus, better imaging techniques are likely to
lead to an increase in the number of leaks detected. How-
ever, over this period the proportion of anastomotic leak-
age diagnosed after colorectal cancer surgery in the West
of Scotland fell from 4.4% to 2.3% (P = 0.002).2 This
suggests that patient selection and surgical techniques
have improved leading to fewer anastomotic leaks. In
addition, the management of those diagnosed with anas-
tomotic dehiscence is likely to have changed with an
increase in nonoperative strategies to treat those with
smaller leaks.15 In addition, the proportion of patients
treated by a specialist colorectal surgeon increased from
13.8% to 67.6% (P < 0.001).2 This increase in specialist
surgery contributed significantly to improvements in
longer term survival and the overall reduction in anasto-
motic leakage over this period. However, specialty of sur-
geon was not independently associated with outcome in
this study.
The influence of older age (≥75 years) and emergency
presentation as predictors of poor outcome after colon
cancer surgery have been previously described.16–18 The
negative influence of advanced age on cancer-specific out-
comes could relate to increased levels of comorbidity,
frailty, and chronic systemic inflammation among the
elderly.18,19 These factors in turn not only influence the
type of treatment received by elderly patients, but may
also lead to an augmented inflammatory response which
is associated with poorer cancer-specific survival.20 Other
factors such as differences in tumor site and mode of pre-
sentation also influence cancer-specific outcomes in the
elderly.21
Emergency presentation of stage II colon cancer with
blood loss, perforation, or obstruction was associated with
poorer cancer-specific survival in this study. Those pre-
senting as an emergency were therefore more likely to
have had abnormal physiology and attenuated inflamma-
tory response at time of surgery leading to poorer short
and longer term cancer-specific outcomes.16,17,20
There is now a large body of evidence that selected
patients with stage II colon cancer can derive a small
but significant survival benefit from adjuvant chemo-
therapy.5 During the period of this study, it was not
routine clinical practice for patients with stage II colon
cancer to be considered for adjuvant therapy out with
the confines of a clinical trial. The finding that
increased age and emergency presentation were associ-
ated with poorer outcomes in this study suggests that
such patients may derive benefit from adjuvant chemo-
therapy if fit to receive such treatment. However, the
current evidence base in these groups is small. There-
fore, further clinical trials of adjuvant chemotherapy in
these high-risk groups are required.
Table 3. The relationship between a clinical risk score and cancer-specific survival in patients undergoing surgery for stage II colon cancer.
Stage II n=871 (%) HR (95% CI) P-value
Cancer-specific survival (%)
1-year 3-year 5-year
Clinical score 0 408 (46.8) 1.00 98.3 91.9 88.7
Clinical score 1 381 (43.7) 2.19 (1.53, 3.14) <0.001 94.0 82.7 78.2
Clinical score 2 82 (9.40) 4.24 (2.65, 6.79) <0.001 92.7 74.4 65.9
Figure 1. The relationship between clinical risk score and cancer-
specific survival in patients undergoing surgery for stage II colon
cancer (Log-rank P < 0.001).
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This modified clinical risk score has important implica-
tions. First, this score can be used as simple and reliable
way for clinicians to identify those patients at high risk of
developing recurrence and dying of their cancer. Second,
these scores provide simple stratification factors for clini-
cal studies and trials. Third, the score may provide a basis
for future staging systems for stage II colon cancer to
which recognized tumor prognostic factors such as intra
or extramural vascular invasion, peritoneal involvement,
margin involvement, tumor perforation, tumor grade,
number of examined lymph nodes, inflammation-based
scores (e.g., modified/optimized Glasgow Prognostic
Score), and comorbidity might be added.22–25 The identi-
fication of high-risk patients who would benefit from
adjuvant chemotherapy is therefore crucial to improve
outcomes. However, no widely adopted reliable method
of predicting response to adjuvant chemotherapy for stage
II colon cancer has been developed or incorporated into
routine clinical practice. The identification of reliable clin-
icopathological and robust molecular prognostic markers
to enable stratified individual patient-specific treatment is
therefore highly desirable.
In summary, the results of this study validate and mod-
ify the use of a simple clinical risk score for patients
undergoing surgery for stage II colon cancer. The score
provides a solid foundation for the future examination of
the impact of additional clinicopathological and treatment
factors on prediction of cancer-specific survival in stage II
colon cancer with the clinical implication of identifying
high-risk patients who may benefit from adjuvant
therapies.
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